Note: This study found no significant biological effects under its experimental conditions. We include all studies for scientific completeness.
Cantu JC, Butterworth JW, Payne JA, Echchgadda I
No Effects Found
Authors not listed · 2024
This COVID treatment study was incorrectly classified as EMF research, highlighting database quality issues.
Plain English Summary
Summary written for general audiences
This study appears to be misclassified in the EMF database - it actually examined treatments for pediatric inflammatory syndrome (PIMS-TS) associated with COVID-19, not electromagnetic field exposure. Researchers tested different anti-inflammatory medications in 237 children and found that methylprednisolone and tocilizumab reduced hospital stays compared to usual care.
Cite This Study
Unknown (2024). Cantu JC, Butterworth JW, Payne JA, Echchgadda I.
Show BibTeX
@article{cantu_jc_butterworth_jw_payne_ja_echchgadda_i_ce2708,
author = {Unknown},
title = {Cantu JC, Butterworth JW, Payne JA, Echchgadda I},
year = {2024},
doi = {10.1016/s2352-4642(23)00316-4},
}Quick Questions About This Study
This appears to be a database classification error. The study examined anti-inflammatory treatments for pediatric COVID syndrome, not electromagnetic field exposure effects on health.
Researchers tested whether medications like methylprednisolone and tocilizumab could reduce hospital stays for 237 children with COVID-related inflammatory syndrome (PIMS-TS).
Yes, children receiving methylprednisolone had shorter hospital stays (6.9 days) compared to usual care (7.6 days), with 87% probability of benefit.
Tocilizumab showed strong evidence of benefit, reducing hospital stays by 3.3 days compared to usual care (6.6 vs 9.9 days) with >99% probability.
Database errors like this create confusion and reduce trust in EMF research repositories, making it harder to identify legitimate electromagnetic field health studies.